A Comparative Investigation of Efficacy and Complications in Light and Deep Chemical Peels

December 19, 2024 updated by: Muhammad Naveed Babur, Superior University
Chemical peeling involves applying substances to the skin to induce controlled damage, which promotes the regeneration of fresh skin cells and enhances the skin's appearance.

Study Overview

Status

Active, not recruiting

Conditions

Intervention / Treatment

Detailed Description

This study will be a cross-sectional analysis with a sample size of 112 patients.

Study Type

Observational

Enrollment (Actual)

112

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Pakistan
    • Punjab
      • Lahore, Punjab, Pakistan, 54000
        • Block E3 E-3 Gulberg III

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

To check the outcomes of Efficacy and Complications in Light and Deep Chemical Peels

Description

Inclusion Criteria:

  • Healthy males and females aged 18-35 years.
  • Willing to provide informed consent and follow the treatment protocol.

Exclusion Criteria:

  • Pregnant or breastfeeding women.
  • Active skin conditions (e.g., acne, eczema).
  • Use of medications that affect skin healing.
  • Known allergies to chemical peel substances.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Dermatological Assessment Score (DAS)
Time Frame: 12 Months
The area-wise percentage involvement of the involved sites is calculated as: 1 = less than 10% area; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; and 6 = more than 90%. The maximum score of PASI is 72. PASI 75 is a 75% reduction of baseline PASI score.
12 Months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Superior University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 1, 2024

Primary Completion (Actual)

August 1, 2024

Study Completion (Estimated)

March 1, 2025

Study Registration Dates

First Submitted

December 19, 2024

First Submitted That Met QC Criteria

December 19, 2024

First Posted (Actual)

March 25, 2025

Study Record Updates

Last Update Posted (Actual)

March 25, 2025

Last Update Submitted That Met QC Criteria

December 19, 2024

Last Verified

December 1, 2024

More Information

Terms related to this study

Other Study ID Numbers

  • MSAHS/Batch-Spring23/057

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe